congresos y reuniones científicas
VSSP modulate innate and adaptive immune response of HIV-1 infected patients: its correlation with clinical outcome
FAINBOIM, LEONARDO; ARRUVITO, LOURDES; BILLORDO, ARIEL; GUTHMANN, MARCELO ; FINK, V; KROLEWIECKI, A; SARACCO, M; GOMEZ, R.E.; GOLD, S; CAHN, P
Congreso; VSSP modulate innate and adaptive immune response of HIV-1 infected patients: its correlation with clinical outcome; 2011
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
We have demonstrated the adjuvant capacity of N-acetyl GM3 combined with Neisserial outer membrane to form very small proteoliposomes (VSSP). Now we performed a randomized, controlled phase II clinical trial, aimed to assess safety and capacity of NAcGM3/VSSP to improve innate and adaptive response of HIV-1 infected individuals, and its association with clinical outcome. HIV-1 infected patients with CD4 count >350 mm3, viral load between 3.000 and 60.000 copies/ml, and no indication for ART were included in Group A, (n=11), with no active treatment (control group) and Group B (n=11), receiving 11 I.M. injections of VSSP + Montanide.